Corcept Therapeutics Incorporated

Financials

Activos totales 571.73 M423.76 M583.43 M621.52 M840.55 M836.65 M Total de pasivos 48.39 M47.95 M81.59 M114.81 M160.96 M188.85 M Capital total 523.34 M375.81 M501.84 M506.7 M679.59 M647.8 M Total de pasivos y patrimonio neto 571.73 M423.76 M583.43 M621.52 M840.55 M836.65 M Deuda total —————— Deuda neta ——————

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

CORT

Financials

Corcept Therapeutics Incorporated

Noticias

Lifyorli de Corcept muestra reducción del 35% en riesgo de muerte por cáncer de ovario

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?

Ejecutivo de Corcept Therapeutics vende acciones por 819.000 dólares

Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade) (NASDAQ:CORT)

Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?

Wolfe Research mejora la calificación de Corcept Therapeutics tras aprobación de la FDA

Wall Street sube mientras el petróleo cae por posibles conversaciones entre EE. UU. e Irán | Benzinga España

La FDA aprueba Lifyorli de Corcept para tratar cáncer de ovario

Las acciones de Corcept Therapeutics se disparan tras la aprobación de su fármaco oncológico por la FDA

Why Corcept's Ovarian Cancer 'Hail Mary' Might Actually Land (NASDAQ:CORT)